Categories Analysis, Earnings, Technology
Earnings preview: Billings in focus as DocuSign prepares for Q2 report
Though DocuSign (NASDAQ: DOCU) entered 2019 on a positive note after last year’s relatively weak performance, the stock is yet to shrug off the volatility. After showing signs of a turnaround in the first quarter, with positive results, the company will be releasing the second-quarter numbers on September 5 after the closing bell.
DocuSign, which provides cloud-based e-signature service, is currently in the process of expanding beyond its core solutions to become a multi-product business.
For the July quarter, market watchers predict a 32% growth in revenues to $220.93 million, while earnings are forecast to edge up to $0.04 per share from last year’s $0.03 per share. The estimate is broadly in line with the management’s expectations.
Pros & Cons
The company’s go-to-market initiatives and efforts to retain the customer base are expected to contribute to revenue this time. Meanwhile, bottom-line growth will be restricted by higher SG&A expenses, which will include $10 million of expenses related to a patent infringement lawsuit.
With new players like Adobe entering the digital signature space, DocuSign is busy consolidating its market with new solutions. For the company, maintaining stable billing growth is pivotal to its overall financial health. If the weakness seen at the beginning of the year persists in the second quarter, it will give a wrong signal to the market and ultimately affect the stock’s performance.
Agreement Cloud
The recent launch of DocuSign Agreement Cloud, designed to make the agreement process more convenient, was an important step towards retaining market share in the long term. It will strengthen the portfolio of the company, whose eSignature solutions rule the market in the key regions.
Looking Back
In the April-quarter, the bottom-line performance improved on the back of a 37% growth in revenues to $214 million. Adjusted earnings per share moved up to $0.07 from $0.01 a year earlier. However, the weaker-than-expected billings growth disappointed the market.
Related: DocuSign Q1 2020 Earnings Conference Call Transcript
During the last trading session of August, DocuSign’s stock hovered near the levels seen at the beginning of the year. Since hitting a record high a year ago, the shares lost about 26%.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on